Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis (Q37853364)

24 August 2017

0 references

1 reference

title

Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis (English)

1 reference

24 August 2017

0 references

1 reference

1 reference

1

1 reference

24 August 2017

Paul Moayyedi

7

0 references

Nicholas Talley

series ordinal

5

object named as

Nicholas J Talley

1 reference

24 August 2017

2

Jean-Paul Achkar

1 reference

24 August 2017

Khurram J Khan

3

1 reference

24 August 2017

Sunanda V Kane

series ordinal

4

1 reference

24 August 2017

John K Marshall

series ordinal

6

1 reference

24 August 2017

language of work or name

English

0 references

publication date

15 March 2011

1 reference

The American Journal of Gastroenterology

24 August 2017

1 reference

24 August 2017

106

1 reference

24 August 2017

4

1 reference

24 August 2017

601-616

1 reference

https://scigraph.springernature.com/pub.10.1038/ajg.2011.67

24 August 2017

0 references

cites work

Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.67

Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.67

An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.67

Cortisone in ulcerative colitis; final report on a therapeutic trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.67

Azathioprine in ulcerative colitis: final report on controlled therapeutic trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.67

The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.67

Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.67

Errors in the conduct of systematic reviews of pharmacological interventions for irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.67

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.67

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.67

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.67

CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.67

Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.67

Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.67

Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.67

Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.67

Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.67

Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.67

The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.67

A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.67

Use of colonic eicosanoid concentrations as predictors of relapse in ulcerative colitis: double blind placebo controlled study on sulphasalazine maintenance treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.67

Olsalazine in maintenance of clinical remission in patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.67

Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.67

Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.67

Optimum dose of olsalazine for maintaining remission in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.67

Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.67

Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.67

Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis - a 6-month placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.67

Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.67

Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.67

Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.67

21 January 2018

Identifiers

DOI

10.1038/AJG.2011.67

1 reference

Dimensions Publication ID

24 August 2017

0 references

1 reference